Everest Medicines Licenses Civorebrutinib to Travere for $1.15B in Rare Kidney Disease Push — Everest Medicines Limited

Event summary

Everest Medicines licenses civorebrutinib (EVER001) to Travere Therapeutics for $112.5M upfront, with up to $1.03B in milestones.
Civorebrutinib is a potential best-in-class BTK inhibitor for rare kidney diseases, including PMN, FSGS, and MCD.
Travere gains exclusive rights outside China and select Asian markets.
Phase 1/2 data showed rapid reductions in autoantibodies and proteinuria in PMN patients.
Everest retains rights in China and certain East/Southeast Asian countries.

The big picture

This deal underscores the growing focus on rare kidney diseases, where unmet needs persist despite recent advances. Travere's expertise in this space complements Everest's dual-engine strategy of partnerships and in-house R&D, positioning civorebrutinib as a potential blockbuster. The $1.15B deal highlights the high stakes in developing next-generation BTK inhibitors for autoimmune-mediated renal conditions.

What we're watching

Clinical Progress: Whether Travere can replicate civorebrutinib's Phase 1/2 success in larger, multi-indication trials.
Commercialization Strategy: How Travere integrates civorebrutinib into its existing rare kidney disease portfolio.
Regulatory Pathway: The pace at which civorebrutinib advances through regulatory approvals in key markets.